Ensayos clínicos

Inclusion Criteria:

- Cohort A: Received a minimum of 1 to a maximum of 3 prior lines of therapy including a
proteasome inhibitor (PI) and immunomodulatory therapy (IMiD), and lenalidomide
refractory per International Myeloma Working Group (IMWG) guidelines

- Cohort B: Received one line of prior therapy including a PI and an IMiD, and disease
progression per IMWG criteria less than or equal to (<=) 12 months after treatment
with autologous stem cell transplantation (ASCT) or <=12 months from the start of
anti-myeloma therapy for participants who have not had an ASCT

- Cohort C: Previously treated with a PI, an IMiD, an anti-CD38 monoclonal antibody and
B-cell maturation antigen (BCMA)-directed therapy

- Cohort D: Newly diagnosed multiple myeloma per IMWG with a history of 4 to 8 total
cycles of initial therapy, including induction, high-dose therapy, and ASCT with or
without consolidation

- Cohort E: Have newly diagnosed multiple myeloma without prior therapy (one cycle of
prior therapy before enrollment is acceptable) and classified as high risk defined as
either: 1) International Staging System (ISS) stage III criteria, Beta 2 microglobulin
greater than or equal to (>=) 5.5 milligram per liter (mg/L) (via local or central
laboratory assessment) or 2) high risk cytogenetic features del(17/17p), t (14;16),
t(14;20), 1q amplification (at least 4 total copies) in at least 20 percent (%) of the
total plasma cell population

- Cohort F:

- Participant must have a documented efficacy response of very good partial response
(VGPR) or better, without progressive disease prior to enrollment, as assessed per
IMWG 2016 criteria

- Received initial therapy as specified below. The dose/schedule of cycles administered
will be as per standard of care. It is acceptable for up to 1 cycle of the
protocol-specified regimens to be missing one of the listed agents (example, held due
to toxicity). Acceptable combinations include: At least 5 to 8 cycles of initial
therapy with daratumumab, bortezomib, lenalidomide and dexamethasone (D-VRd). The
dose/schedule of cycles administered will be as per standard of care or; at least 4 to
8 cycles of initial therapy with daratumumab, lenalidomide and dexamethasone (D-Rd)
or; at least 4 to 8 cycles of initial therapy with a carfilzomib-based triplet or
quadruplet regimen

- Cohorts A, B, C, E:

- Serum monoclonal paraprotein (M-protein) level greater than or equal to (>=) 1.0 gram
per deciliter (g/dL) or urine M-protein level >=200 milligram (mg)/24 hours

- Light chain multiple myeloma in whom only measurable disease is by serum free light
chain (FLC) levels in the serum: Serum immunoglobulin FLC >=10 mg/dL and abnormal
serum immunoglobulin kappa lambda FLC ratio

- Cohort A: For participants with neither serum nor urine measurable disease, baseline
positron emission tomography/ computed tomography (PET/CT) or whole -body magnetic
resonance imaging (MRI) may be used to satisfy the measurable disease criteria. A
minimum of one lesion with a bi-dimensional measurement of at least 1 centimeter
(cm)*1 cm is required

- Cohorts B, C: For participants with neither serum nor urine measurable disease,
baseline positron emission tomography/ computed tomography (PET/CT) or whole body
magnetic resonance imaging (MRI) may be used to satisfy the measurable disease
criteria

- Cohorts A, B, C, D, E, F: Eastern Cooperative Oncology Group (ECOG) performance status
grade of 0 or 1

Exclusion Criteria:

- Cohorts A, B, D, F: Any therapy that is targeted to BCMA

- Cohorts A, B, C, D, F: Prior treatment with chimeric antigen receptor T (CAR-T)
therapy directed at any target

- Cohorts A, B, C, D, F:

- Ongoing toxicity from previous anticancer therapy must resolve to baseline levels or
to Grade 1 or less except for alopecia or peripheral neuropathy

- Received a cumulative dose of corticosteroids equivalent to >=70 mg of prednisone
within the 7 days (Cohort A, B, C, F) or 14 days (Cohort D) prior to apheresis

- Serious underlying medical condition, such as (a) evidence of active viral or
bacterial infection requiring systemic antimicrobial therapy, or uncontrolled systemic
fungal infection; (b) active autoimmune disease or a history of autoimmune disease
within 3 years; (c) overt clinical evidence of dementia or altered mental status; (d)
any history of Parkinson's disease or other neurodegenerative disorder

- Cohorts A, B, C, D, E, F: Known active, or prior history of central nervous system
(CNS) involvement or exhibits clinical signs of meningeal involvement of multiple
myeloma

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated  8/16/22. Questions regarding updates should be directed to the study team contact.